<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Testicular cancer TNM staging AJCC UICC 8th edition</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Testicular cancer TNM staging AJCC UICC 8th edition</h1>
<div class="graphic"><div class="figure"><div class="ttl">Testicular cancer TNM staging AJCC UICC 8th edition</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup width="85%"></colgroup> <tbody> <tr> <td class="subtitle1_left" colspan="2">Primary tumor (T)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="2">Clinical T (cT)</td> </tr> <tr class="highlight_gray_text divider_bottom"> <td class="indent1"><strong>cT category</strong></td> <td><strong>cT criteria</strong></td> </tr> <tr> <td class="indent2">cTX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class="indent2">cT0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class="indent2">cTis</td> <td>Germ cell neoplasia <em>in situ</em></td> </tr> <tr> <td class="indent2">cT4</td> <td>Tumor invades scrotum with or without vascular/lymphatic invasion</td> </tr> <tr class="divider_bottom"> <td class="indent2" colspan="2"><em>NOTE:</em> Except for Tis confirmed by biopsy and T4, the extent of the primary tumor is classified by radical orchiectomy. TX may be used for other categories for clinical staging.</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="2">Pathological T (pT)</td> </tr> <tr class="highlight_gray_text divider_bottom"> <td class="indent1"><strong>pT category</strong></td> <td><strong>pT criteria</strong></td> </tr> <tr> <td class="indent2">pTX</td> <td>Primary tumor cannot be assessed</td> </tr> <tr> <td class="indent2">pT0</td> <td>No evidence of primary tumor</td> </tr> <tr> <td class="indent2">pTis</td> <td>Germ cell neoplasia <em>in situ</em></td> </tr> <tr> <td class="indent2">pT1</td> <td>Tumor limited to testis (including rete testis invasion) without lymphovascular invasion</td> </tr> <tr> <td class="indent3">pT1a*</td> <td>Tumor smaller than 3 cm in size</td> </tr> <tr> <td class="indent3">pT1b*</td> <td>Tumor 3 cm or larger in size</td> </tr> <tr> <td class="indent2">pT2</td> <td>Tumor limited to testis (including rete testis invasion) with lymphovascular invasion <strong>or</strong><br/> Tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion</td> </tr> <tr> <td class="indent2">pT3</td> <td>Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion</td> </tr> <tr> <td class="indent2">pT4</td> <td>Tumor invades scrotum with or without lymphovascular invasion</td> </tr> <tr class="divider_bottom"> <td class="indent2" colspan="2">* Subclassification of pT1 applies only to pure seminoma.</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="2">Regional lymph nodes (N)</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="2">Clinical N (cN)</td> </tr> <tr class="highlight_gray_text divider_bottom"> <td class="indent1"><strong>cN category</strong></td> <td><strong>cN criteria</strong></td> </tr> <tr> <td class="indent2">cNX</td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class="indent2">cN0</td> <td>No regional lymph node metastasis</td> </tr> <tr> <td class="indent2">cN1</td> <td>Metastasis with a lymph node mass 2 cm or smaller in greatest dimension <strong>or</strong><br/> Multiple lymph nodes, none larger than 2 cm in greatest dimension</td> </tr> <tr> <td class="indent2">cN2</td> <td>Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension <strong>or</strong><br/> Multiple lymph nodes, any one mass larger than 2 cm but not larger than 5 cm in greatest dimension</td> </tr> <tr class="divider_bottom"> <td class="indent2">cN3</td> <td>Metastasis with a lymph node mass larger than 5 cm in greatest dimension</td> </tr> <tr class="divider_bottom"> <td class="subtitle2_left" colspan="2">Pathological N (pN)</td> </tr> <tr class="highlight_gray_text divider_bottom"> <td class="indent1"><strong>pN category</strong></td> <td><strong>pN criteria</strong></td> </tr> <tr> <td class="indent2">pNX</td> <td>Regional lymph nodes cannot be assessed</td> </tr> <tr> <td class="indent2">pN0</td> <td>No regional lymph node metastasis</td> </tr> <tr> <td class="indent2">pN1</td> <td>Metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension</td> </tr> <tr> <td class="indent2">pN2</td> <td>Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension; or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor</td> </tr> <tr class="divider_bottom"> <td class="indent2">pN3</td> <td>Metastasis with a lymph node mass larger than 5 cm in greatest dimension</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="2">Distant metastasis (M)</td> </tr> <tr class="divider_bottom"> <td><strong>M category</strong></td> <td><strong>M criteria</strong></td> </tr> <tr> <td class="indent1">M0</td> <td>No distant metastases</td> </tr> <tr> <td class="indent1">M1</td> <td>Distant metastases</td> </tr> <tr> <td class="indent2">M1a</td> <td>Nonretroperitoneal nodal or pulmonary metastases</td> </tr> <tr class="divider_bottom"> <td class="indent2">M1b</td> <td>Nonpulmonary visceral metastases</td> </tr> <tr class="divider_top"> <td class="subtitle1_left" colspan="2">Serum markers (S)<sup>¶</sup></td> </tr> <tr class="divider_bottom"> <td><strong>S category</strong></td> <td><strong>S criteria</strong></td> </tr> <tr> <td class="indent1">SX</td> <td>Marker studies not available or not performed</td> </tr> <tr> <td class="indent1">S0</td> <td>Marker study levels within normal limits</td> </tr> <tr> <td class="indent1">S1</td> <td>LDH &lt;1.5 × N<sup>Δ</sup> <strong>and</strong> hCG (mIU/mL) &lt;5000 <strong>and</strong> AFP (ng/mL) &lt;1000</td> </tr> <tr> <td class="indent1">S2</td> <td>LDH 1.5 to 10 × N<sup>Δ</sup> <strong>or</strong> hCG (mIU/mL) 5000 to 50,000 <strong>or</strong> AFP (ng/mL) 1000 to 10,000</td> </tr> <tr> <td class="indent1">S3</td> <td>LDH &gt;10 × N<sup>Δ</sup> <strong>or</strong> hCG (mIU/mL) &gt;50,000 <strong>or</strong> AFP (ng/mL) &gt;10,000</td> </tr> <tr> <td class="indent1" colspan="2">¶ Markers used for risk classification are postorchiectomy.<br/> Δ N indicates the upper limit of normal for the LDH assay.</td> </tr> </tbody></table></div><div class="graphic_footnotes">TNM: Tumor, Node, Metastasis; AJCC: American Joint Committee on Cancer; UICC: Union for International Cancer Control; LDH: lactate dehydrogenase; hCG: human chorionic gonadotropin; AFP: alpha-fetoprotein.</div><div class="graphic_reference">Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. Corrected at 4th printing, 2018.</div><div id="graphicVersion">Graphic 110731 Version 11.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
